Skip to main content
SpringerLink
Log in

Palliative und supportive Therapie bei Patienten mit fortgeschrittenem Prostatakarzinom

Palliative and supportive treatment options in patients with advanced prostate cancer

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Lebensqualität und die Verhinderung von Komplikationen stehen bei Patienten mit fortgeschrittenem Prostatakarzinom zunehmend im Vordergrund. Neben der Beherrschung lokaler Probleme wie Obstruktion, Makrohämaturie oder Lymphödemen nimmt dabei die Behandlung ossärer Metastasen und deren Komplikationen einen wichtigen Stellenwert ein. Analgetische Maßnahmen, Bisphosphonate, Strahlentherapie, enossale Schmerztherapie und neurochirurgische Verfahren stehen zur Verfügung. Eine Spinalkanalkompression mit akuten motorischen oder sensorischen Ausfällen bedarf sofortiger neurochirurgischer und/oder strahlentherapeutischer Behandlung. Eine bestehende Tumoranämie sollte adäquat behandelt werden.

Abstract

In patients with advanced prostate cancer, quality of life and prevention of complications come to the fore. Besides handling local complications such as obstruction, hematuria and lymphedema, treatment of bone metastases and their complications is of great importance. Analgesic measures, bisphosphonates, radiation therapy, radionuclide therapy and neurosurgical procedures are available. Spinal cord compression with acute motor and sensory deficiency requires immediate neurosurgical and/or radiation therapy. Tumor anemia should be treated appropriately.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S (2006) Palliative transurethral resection of the prostate: functional outcome and impact on survival. BJU Int 99(1): 56–59

    Article  Google Scholar 

  2. Crain DS, Amling CL, Kane CJ (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171: 668–671

    Article  PubMed  Google Scholar 

  3. Chang CC, Kuo JY, Chen KK et al. (2006) Transurethral prostatic resection for acute urinary retention in patients with prostate cancer. J Chin Med Assoc 69: 21–25

    PubMed  Google Scholar 

  4. Gnanapragasam VJ, Kumar V, Langton D et al. (2006) Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. Int J Urol 13: 711–715

    Article  PubMed  Google Scholar 

  5. Kuntz RM (2006) Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 49: 961–969

    Article  PubMed  Google Scholar 

  6. Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175: 1428–1432

    Article  PubMed  Google Scholar 

  7. Uthappa MC, Cowan NC (2005) Retrograde or antegrade double-pigtail stent placement for malignant ureteric obstruction? Clin Radiol 60: 608–612

    Article  PubMed  Google Scholar 

  8. Laube N, Bradenahl J, Meissner A et al. (2006) Plasma-deposited carbon coating on urological indwelling catheters: Preventing formation of encrustations and consecutive complications. Urologe A 45: 1163–1169

    Article  PubMed  Google Scholar 

  9. Harris MR, Speakman MJ (2006) Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit? Prostate Cancer Prostatic Dis 9: 42–44

    Article  PubMed  Google Scholar 

  10. Romero FR, Broglio M, Pires SR et al. (2005) Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol 31: 117–124

    Article  PubMed  Google Scholar 

  11. Kirkova J, Oneschuk D, Hanson J (2005) Deep vein thrombosis (DVT) in advanced cancer patients with lower extremity edema referred for assessment. Am J Hosp Palliat Care 22: 145–149

    Article  PubMed  Google Scholar 

  12. Giess CS, Bach AM, Hann LE (2001) Lower extremity venous sonography in the high-risk cancer population: one leg or two? AJR Am J Roentgenol 176: 1049–1052

    PubMed  Google Scholar 

  13. Vignes S, Priollet P (2002) Lymphology in 2002. From diagnosis to treatment of lymphedemas. Rev Med Interne 23(Suppl 3): 436–441

    PubMed  Google Scholar 

  14. Tiwari A, Cheng KS, Button M et al. (2003) Differential diagnosis, investigation, and current treatment of lower limb lymphedema. Arch Surg 138: 152–161

    Article  PubMed  Google Scholar 

  15. Shrubb D, Mason W (2006) The management of deep vein thrombosis in lymphoedema: a review. Br J Community Nurs 11: 292–297

    PubMed  Google Scholar 

  16. WHO (1996) Cancer pain relief, 2nd edn. WHO, Genf

  17. Smith MR (2002) Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21: 159–166

    Article  PubMed  Google Scholar 

  18. Oefelein MG, Ricchuiti V, Conrad W et al. (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724–1728

    Article  PubMed  Google Scholar 

  19. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610

    Article  PubMed  Google Scholar 

  20. Smith MR, McGovern FJ, Zietman AL et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948–955

    Article  PubMed  Google Scholar 

  21. Diamond TH, Winters J, Smith A et al. (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92: 1444–1450

    Article  PubMed  Google Scholar 

  22. Coleman RE, Purohit OP, Vinholes JJ, Zekri J (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80: 1686–1690

    Article  PubMed  Google Scholar 

  23. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136–140

    Article  PubMed  Google Scholar 

  24. Saad F, Gleason DM, Murray R et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458–1468

    PubMed  Google Scholar 

  25. Ernst DS, Tannock IF, Winquist EW et al. (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335–3342

    Article  PubMed  Google Scholar 

  26. Dearnaley DP, Sydes MR, Mason MD et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95: 1300–1311

    PubMed  Google Scholar 

  27. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 259–260

    Article  PubMed  Google Scholar 

  28. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104: 83–93

    Article  PubMed  Google Scholar 

  29. Chow E, Wu J, Loblaw A, Perez CA (2003) Radiotherapeutic approaches to metastatic disease. World J Urol 21: 229–242

    Article  PubMed  Google Scholar 

  30. Nagata M, Ueda T, Komiya A et al. (2003) Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer. Prostate Cancer Prostatic Dis 6: 169–173

    Article  PubMed  Google Scholar 

  31. Tazi H, Manunta A, Rodriguez A et al. (2003) Spinal cord compression in metastatic prostate cancer. Eur Urol 44: 527–532

    Article  PubMed  Google Scholar 

  32. Hoskin PJ, Grover A, Bhana R (2003) Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol 68: 175–180

    Article  PubMed  Google Scholar 

  33. Rades D, Stalpers LJ, Veninga T et al. (2005) Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 23: 3366–3375

    Article  PubMed  Google Scholar 

  34. Maranzano E, Bellavita R, Rossi R et al. (2005) Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 23: 3358–3365

    Article  PubMed  Google Scholar 

  35. Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6: 392–400

    Article  PubMed  Google Scholar 

  36. Sartor O (2003) Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr Oncol Rep 5: 258–262

    PubMed  Google Scholar 

  37. Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45: 1358–1365

    PubMed  Google Scholar 

  38. Bauman G, Charette M, Reid R, Sathya J (2005) Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 75: 258–270

    PubMed  Google Scholar 

  39. Maini CL, Sciuto R, Romano L, Bergomi S (2003) Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. J Exp Clin Cancer Res 22: 71–74

    PubMed  Google Scholar 

  40. Byrne TN, Borges LF, Loeffler JS (2006) Metastatic epidural spinal cord compression: update on management. Semin Oncol 33: 307–311

    Article  PubMed  Google Scholar 

  41. Klimo P Jr, Thompson CJ, Kestle JR, Schmidt MH (2005) A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neurooncology 7: 64–76

    Google Scholar 

  42. Cella D (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology (Williston Park) 20: 25–28

    Google Scholar 

  43. Littlewood TJ, Nortier J, Rapoport B et al. (2003) Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21: 169–180

    Article  PubMed  Google Scholar 

  44. Wild C, Jonas S (2001) Health policy decisions between rationing and rationalization – exemplified by erythropoietin in tumor anemia. Gesundheitswesen 63: 221–225

    Article  PubMed  Google Scholar 

  45. Seidenfeld J, Piper M, Flamm C et al. (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–1214

    Article  PubMed  Google Scholar 

  46. Tannock IF, de Wit R, Berry WR et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  PubMed  Google Scholar 

  47. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, 81675, Ismaninger Straße 22, München, Deutschland

    T. Maurer, M. Retz & J.E. Gschwend

Authors
  1. T. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.E. Gschwend
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Maurer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maurer, T., Retz, M. & Gschwend, J. Palliative und supportive Therapie bei Patienten mit fortgeschrittenem Prostatakarzinom. Urologe 46, 30–35 (2007). https://doi.org/10.1007/s00120-006-1271-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1271-8

Schlüsselwörter

Keywords

Search

Navigation